Oligonucleotide and mRNA analytical workflows

Significance of the topic

Oligonucleotide and mRNA therapeutics present unique analytical challenges that directly affect product safety, efficacy, and regulatory approval. Robust, sensitive and orthogonal analytical workflows are essential to define critical quality attributes (CQAs), detect and quantify impurities and sequence variants, and to support stability and batch-release decisions under GMP. Integrated analytics reduce development risk, speed candidate selection, and provide the traceability and reproducibility required for regulatory submissions and commercial manufacturing.

Objectives and overview of the workflow

The documented workflow aims to provide a seamless analytical continuum from early-stage characterization to routine GMP release testing for oligonucleotides and mRNA. Key objectives are: to resolve closely related molecular species, confirm sequence and structure, identify impurities (including truncated species and sequence variants), assess mRNA integrity and features (5' cap efficiency, poly(A) tail heterogeneity), and establish stability‑indicating methods and reproducible QC procedures suitable for operational use and regulatory defense.

Methodology and analytical approach

Analytical strategies combine high-resolution liquid chromatography and mass spectrometry with targeted enzymatic mapping and robust data systems. Core elements include:

• High-resolution reversed-phase UHPLC separations to separate full-length molecules from closely related impurities and truncation products;
• Diode-array and variable-wavelength detection for general purity profiling and monitoring chromatographic behavior;
• High-resolution mass spectrometry (HRMS) and single-quadrupole MS for mass confirmation, sequence variant detection and intact mass profiling;
• Enzymatic mapping (RNase T1/A workflows) to localize sequence changes and validate primary structure;
• Integrity assessments for mRNA (size distribution, degradation products), plus characterization of 5' capping efficiency and poly(A) tail heterogeneity;
• Stability-indicating impurity methods and sensitive assays for truncated species to support shelf-life and formulation decisions;
• Validated CDS and biopharma analysis software for data capture, processing, and regulatory-compliant traceability.

Method development emphasizes orthogonality (chromatography + MS + enzymatic mapping), sensitivity for low‑level impurities, and transferability to routine QC environments.

Instrumentation used

The workflow leverages a portfolio of chromatography, MS, enzymatic digestion, purification and software tools. Representative instrumentation and consumables include:

• UHPLC systems: Vanquish Amplify UHPLC platform for high-resolution separations;
• Detectors: Vanquish Diode Array Detector (DAD) and Variable Wavelength Detector (VWD) with semi-micro inert flow cells;
• Columns and stationary phases: SurePac Oligo RP MDi reversed-phase columns in multiple formats (capillary and analytical lengths) tailored for oligonucleotide separations;
• Enzymatic mapping kits: SMART Digest RNase columns and RNase T1/A kits for controlled oligonucleotide digestion and mapping;
• Mass spectrometers: a range from single-quadrupole (ISQ EM) to high-resolution Orbitrap platforms (Exploris MX, Exploris 240, Excedion) for intact mass and fragment analysis;
• Purification automation: KingFisher Flex magnetic-bead purification system to support sample cleanup and prep workflows;
• Consumables: chromatography vials, specialized flow cells and column formats optimized for bio-oligonucleotide analysis;
• Software and data systems: Chromeleon Chromatography Data System and BioPharma Finder for data processing, sequence confirmation and reporting.

Each instrument class supports specific CQA measurements: chromatographic systems resolve species and provide quantitative purity data; MS provides mass confirmation and variant profiling; enzymatic mapping localizes sequence changes; software ensures traceable processing and multi-attribute data consolidation.

Main results and discussion

Although the source document is a solutions overview rather than a primary research report, it asserts capabilities relevant to modern oligonucleotide and mRNA analytics: high-resolution separation of closely related species; reliable sequence confirmation and structural characterization; sensitive detection of truncated species and sequence variants; assessment of mRNA integrity, cap efficiency and poly(A) heterogeneity; and stability-indicating impurity monitoring. These combined techniques enable early CQA identification and the construction of regulatory-defensible impurity profiles.
Practical considerations and caveats include:

• Vendor-provided platforms facilitate integration but method performance depends on careful optimization (mobile phase, temperature, column selection) and sample preparation to avoid artefacts;
• Matrix effects, salt adducts and ion-pairing reagents can complicate MS interpretation, so orthogonal confirmation (e.g., enzymatic mapping or alternative chromatographic modes) remains important;
• High-resolution MS improves variant discrimination, yet validation for routine QC requires robust procedures, defined acceptance criteria and demonstration of precision, accuracy and limit of detection/quantitation;
• Scale-up from characterization to QC/batch release necessitates method ruggedness testing and transfer protocols between labs or instruments.

Benefits and practical applications

The integrated workflow supports multiple stages of an RNA therapeutic program:

• Early development: candidate characterization, sequence confirmation, impurity profiling to select lead molecules;
• Process development: monitoring truncation and chemical modifications introduced during synthesis and purification;
• Formulation and stability studies: stability-indicating assays to define shelf life and storage conditions;
• GMP QC and lot release: reproducible UHPLC-MS assays and traceable data systems for regulatory submissions and manufacturing control;
• Comparability and CMC: analytical packages that support comparability studies after process changes or scale-up.

Future trends and applications

Analytical needs for oligonucleotide and mRNA therapeutics are evolving; expected trends include:

• Greater automation and higher-throughput sample preparation to support screening of multiple candidates and larger clinical programs;
• Advances in native and top‑down MS methods for intact oligonucleotide sequencing and higher-order structural analysis;
• Improved data analytics, including machine-learning approaches, for peak annotation, variant calling and multi-attribute monitoring;
• Standardization of CQA panels and cross-laboratory method harmonization to streamline regulatory review and comparability;
• Integration of analytics into manufacturing (PAT) for near-real-time monitoring of critical impurities and product quality;
• Continued development of orthogonal technologies (capillary electrophoresis, ion-pair LC alternatives) to reduce dependence on single-method interpretations.

Conclusion

Comprehensive analytical workflows combining high-resolution UHPLC, mass spectrometry, enzymatic mapping and robust software form the backbone of responsible oligonucleotide and mRNA product development. These methods provide the sensitivity and specificity needed to define CQAs, support stability and release testing, and present defensible impurity profiles to regulators. Successful implementation requires method optimization, orthogonal confirmation, and validated data systems to ensure reproducibility in routine GMP environments.

References

• Thermo Fisher Scientific. Oligonucleotide Analysis Solutions brochure. 2026.